Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07816328) titled 'Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks' on Sept. 7.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Chronic Spontaneous Urticaria
Intervention:
Drug: Remibrutinib
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: November 9, 2026
Target Sample Size: 382
To know ...